Artwork

Content provided by Research To Practice. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Research To Practice or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dr Jeff Sharman Comments on the Use of BTK Inhibitors as Treatment for Patients with SARS-CoV-2

27:40
 
Share
 

Manage episode 271844748 series 2787983
Content provided by Research To Practice. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Research To Practice or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2.

Additional Resources

  • Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract
  • AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release]. April 14, 2020.
  • Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract
  • COVID-19 and CLL: Frequently Asked Questions. Hematology.org. May 6, 2020;Version 1.3.
  • Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence
  • Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence
  • Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text
  continue reading

239 episodes

Artwork
iconShare
 
Manage episode 271844748 series 2787983
Content provided by Research To Practice. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Research To Practice or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2.

Additional Resources

  • Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract
  • AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release]. April 14, 2020.
  • Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract
  • COVID-19 and CLL: Frequently Asked Questions. Hematology.org. May 6, 2020;Version 1.3.
  • Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence
  • Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence
  • Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text
  continue reading

239 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide